ArticleJournal of comparative effectiveness research2025
Matching-adjusted indirect comparison of ribociclib + nonsteroidal aromatase inhibitor versus abemaciclib + endocrine therapy in hormone receptor-positive/HER2-negative early breast cancer.
Stephen Chia et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.